Publications by authors named "David Pryor"

Claim this Profile
D
Dosimetric Clues to Addressing Urinary Toxicity Following Stereotactic Prostate Radiation Therapy.
Michael Cardoso, Matthew Richardson, Phillip Chlap, Sarah Keats, Alan Glyde, David Pryor

Adv Radiat Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney.
Muhammad Ali, Rohann J M Correa, David Pryor, Braden Higgs, Swetha Sridharan

Int J Radiat Oncol Biol Phys· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial.
Constanza Vargas, Joe Carrello, Mathias Bressel, Mark Sidhom, Charles Lin, David Pryor

Int J Radiat Oncol Biol Phys· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update of clinical practice guidelines for the management of patients with sarcoma.
David E Gyorki, Susie Bae, Richard Carey Smith, Denise A Caruso, David Coker, David Pryor

ANZ J Surg· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer.
Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor

BJU Int· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the efficacy of stereotactic radiotherapy for metastatic colorectal cancer: A retrospective review of clinical outcomes.
Beini Chen, Justin Smith, Revadhi Chelvarajah, Alexandra Knesl, Parushka Moodley, David Pryor

J Radiosurg SBRT· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Matthew P Deek, Philip Sutera, Yuezhou Jing, Robert Gao, Emily Rothman, David Pryor

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II.
Mathieu Gaudreault, Nicholas Hardcastle, Price Jackson, Lachlan McIntosh, Braden Higgs, David Pryor

Int J Radiat Oncol Biol Phys· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner, David I Pryor

Lancet· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial.
Eric Wegener, Mark Sidhom, David Pryor, Joseph Bucci, Kenway Yeoh

Eur Urol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radio-opaque contrast agents for liver cancer targeting with KIM during radiation therapy (ROCK-RT): an observational feasibility study.
Natalie Plant, Adam Mylonas, Chandrima Sengupta, Doan Trang Nguyen, Shona Silvester, David Pryor

Radiat Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment accuracy of standard linear accelerator-based prostate SBRT: the delivered dose assessment of patients treated within two major clinical trials using an in-house position monitoring system.
Sankar Arumugam, Tony Young, Catherine Jones, David Pryor, Mark Sidhom

Front Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC).
Alan Wigg, Jonathan Tibballs, Richard Woodman, Katherine Stuart, Hien Le, David Pryor

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic ablative radiotherapy for primary kidney cancer - Authors' reply.
Shankar Siva, Daniel Moon, David Pryor

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben G L Vanneste, David Pryor

Lancet Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers and enablers of active surveillance for prostate cancer: a qualitive study of clinicians.
Trent A Pattenden, Isaac A Thangasamy, Wee Loon Ong, Dhanika Samaranayke, Andrew Morton, David Pryor

BJU Int· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term cost outcomes among commercially insured patients undergoing bariatric surgical procedures.
Sonali Shambhu, Qinli Ma, Aliza S Gordon, David Pryor, Joseph A Karam

Obes Sci Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation.
Hang Min, Jason Dowling, Michael G Jameson, Kirrily Cloak, Joselle Faustino, David Pryor

Radiother Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost.
Matthew Richardson, Mark Sidhom, Paul Keall, Lucy Leigh, Helen Ball, David Pryor

Int J Radiat Oncol Biol Phys· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases.
Shankar Siva, Pitchaya Sakyanun, Tao Mai, Wenchang Wong, Adeline Lim, David Pryor

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial.
Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel

Contemp Clin Trials Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refining stereotactic body radiation therapy as a bridge to transplantation for hepatocellular carcinoma: An institutional experience.
Beini Chen, Nick Butler, Thomas O'Rourke, Peter Hodgkinson, Katherine Stuart, David Pryor

J Med Imaging Radiat Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modern Active Surveillance in Prostate Cancer: A Narrative Review.
Trent A Pattenden, Dhanika Samaranayke, Andrew Morton, Wee Loon Ong, Declan G Murphy, David Pryor

Clin Genitourin Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association.
Angela M Hong, Helen Lo, Anna Lawless, Deborah Zhou, Susie Bae, David Pryor

Radiother Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus.
Ashika D Maharaj, John Lubel, Eileen Lam, Paul J Clark, Oliver Duncan, David Pryor

Hepatol Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis